Ruplizumab

Drug Profile

Ruplizumab

Alternative Names: 5c8; 5c8 humanised monoclonal antibody; Anti-CD154 monoclonal antibody; Anti-CD40 ligand antibody; Anti-CD40 ligand monoclonal antibody; Anti-CD40 ligand monoclonal antibody 5c8; Anti-gp39 monoclonal antibody - Biogen; Antova; BG 9588; CD40 ligand monoclonal antibody - Biogen; hu5c8; Humanised CD40 ligand antibody/5c8; T cell-B cell activation molecule; T-BAM

Latest Information Update: 07 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Haemophilia A; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Renal transplant rejection; Systemic lupus erythematosus

Most Recent Events

  • 28 Aug 2001 A study has been added to the adverse events and Transplant Rejection therapeutic trials sections
  • 22 Aug 2001 Anti-CD40 ligand monoclonal antibody 5c8 is now called Ruplizumab
  • 28 Apr 2000 A clinical study has been added to the therapeutic trials section of haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top